Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $19.33 Average Price Target from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $19.33.

A number of analysts have recently issued reports on VYGR shares. HC Wainwright started coverage on Voyager Therapeutics in a research note on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price target on the stock. Wells Fargo & Company raised Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $9.00 to $14.00 in a research note on Tuesday, January 2nd. Citigroup assumed coverage on Voyager Therapeutics in a research note on Thursday, March 7th. They set a “buy” rating and a $16.00 price objective on the stock. Guggenheim assumed coverage on Voyager Therapeutics in a research note on Tuesday, March 26th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th.

Hedge Funds Weigh In On Voyager Therapeutics

Large investors have recently modified their holdings of the business. Kestra Advisory Services LLC acquired a new position in shares of Voyager Therapeutics in the 3rd quarter valued at $980,000. Ritholtz Wealth Management lifted its stake in Voyager Therapeutics by 11.8% during the 4th quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock worth $167,000 after acquiring an additional 2,089 shares in the last quarter. Alps Advisors Inc. acquired a new position in Voyager Therapeutics during the 3rd quarter worth about $294,000. China Universal Asset Management Co. Ltd. acquired a new position in Voyager Therapeutics during the 4th quarter worth about $43,000. Finally, Aigen Investment Management LP acquired a new position in Voyager Therapeutics during the 3rd quarter worth about $109,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR opened at $8.24 on Thursday. The business’s 50 day moving average price is $8.78 and its 200-day moving average price is $7.95. The firm has a market capitalization of $447.44 million, a PE ratio of 2.67 and a beta of 0.96. Voyager Therapeutics has a 1 year low of $6.06 and a 1 year high of $14.34.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. The firm had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. As a group, analysts expect that Voyager Therapeutics will post -1.64 earnings per share for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.